{"favorite_id": 3825, "calc_type": "", "dosing": false, "full_title_en": "Barcelona-Clinic Liver Cancer (BCLC) Staging Classification and Treatment Guidelines", "short_title_en": "BCLC Staging Classification", "medium_description_en": "Determines progression of disease and proper treatment course for patients with HCC.", "short_description_en": "Determines progression and treatment course in HCC,", "before_use": "", "instructions_en": "", "purpose_en": ["Prognosis", "Treatment"], "disease_en": ["Hepatocellular Carcinoma"], "specialty_en": ["Hematology and Oncology", "Hepatology", "Hospitalist Medicine", "Internal Medicine", "Surgery (General)"], "chief_complaint_en": ["Abdominal Pain"], "system_en": ["Gastrointestinal"], "search_abbreviation_en": ["chemo", "hcc"], "slug": "barcelona-clinic-liver-cancer-bclc-staging-classification-treatment-guidelines", "seo": {"meta_description_en": "The BCLC Staging Classification determines progression of disease and proper treatment course for patients with HCC.", "keywords_en": "barcelona, barcelona clinic, llovet score, hcc treatment guidelines, hcc, hepatocellular carcinoma"}, "content": {"how_to_use": {"use_case_en": "<p>Patients diagnosed with hepatocellular carcinoma (HCC).</p>", "pearls_pitfalls_en": "<ul> <li>Classifies hepatocellular carcinoma into one of 4 stages (A-D, with 4 subgroups in stage A), with corresponding recommendations for treatment modalities.</li> <li>Takes into account tumor features AND liver functional status, which are both known to affect prognosis.</li> <li>Also accounts for presence of cancer-related symptoms.</li> <li>Staging system of choice of the&nbsp;American Association for the Study of Liver Disease &nbsp;(AASLD) and&nbsp;European Association for the Study of the Liver (EASL).</li> </ul>", "why_use_en": "<ul> <li>Links stage and prognosis to treatment strategy.</li> <li>Alternative staging systems include TNM and Okuda classifications. TNM staging only accounts for tumor/node/metastasis characteristics (excludes liver function and patient functional status) and Okuda classification is less precise in stratifying earlier-stage tumors.</li> <li><calculator id='340'>Child-Pugh</calculator> and <calculator id='78'>MELD</calculator> scores also stratify HCC patients by prognostic factors.</li> </ul>"}, "next_steps": {"advice_en": "<ul> <li>Patients with stage A HCC (early) should be considered for surgical resection/orthotopic liver transplant (OLT) with intent to cure.</li> <li>Patients with stage B or C HCC (intermediate or advanced, respectively) should be considered for palliative treatment including transarterial chemoembolization (TACE) or novel chemotherapy agents.</li> <li>Patients with stage D HCC (end-stage) should undergo supportive treatment only.</li> </ul>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p><img src=\"https://cdn-web-img.mdcalc.com/content/BCLC_diagram.png\" alt=\"Algorithm showing the BCLC classification.\" width=\"1600\" height=\"1600\" /></p>", "more_info_en": "", "evidence_based_medicine_en": "<ul> <li>The Barcelona Clinic Liver Cancer (BCLC) staging classification was developed by Llovet, Br\u00fa and Bruix in Barcelona in 1999. Multiple studies were evaluated for prognostic factors and outcomes after treatment.&nbsp;</li> <li>Cilio and colleagues validated the study in an Italian population of 187 patients over 9 years, showing that the BCLC performed better than the Okuda and other classifications, in terms of survival.</li> </ul>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/10518312", "text": "Llovet JM, Br\u00fa C, Bruix J.Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-38."}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/20175034", "text": "Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010 Feb;30(1):61-74. doi: 10.1055/s-0030-1247133. Epub 2010 Feb 19."}, {"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2023920/", "text": "Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB\u202f: The Official Journal of the International Hepato Pancreato Biliary Association. 2005;7(1):35-41. doi:10.1080/13651820410024058."}], "Validation": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/14672623", "text": "Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol. 2004;40:124\u201331."}, {"href": "http://www.aasld.org/sites/default/files/guideline_documents/HCCUpdate2010.pdf", "text": "Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199."}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "creator": [{"name": "Dr. Josep Llovet", "creator_info": {"deceased": null, "about_en": "<p>Josep Llovet, MD, is a professor of medicine and founder and director of the Liver Cancer Program at Mount Sinai Hospital. He was the president, secretary and founder of the International Liver Cancer Association (ILCA) and Chairman of the European Clinical Practice Guidelines of management of liver cancer (EASL-EORTC). He is an active researcher investigating the pathogenesis and treatment of liver cancer.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/default.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Llovet+JM%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Child-Pugh grade", "name": "cp", "options": [{"label": "A", "value": 1}, {"label": "B", "value": 2}, {"label": "C", "value": 3}], "conditionality": "", "show_points": false, "optional": false}, {"type": "radio", "label_en": "Cancer stage", "name": "stage", "options": [{"label": "Very early stage (single, carcinoma in situ)", "value": 0}, {"label": "Early stage (1 nodule <5cm up to 3 nodules <3cm)", "value": 1}, {"label": "Intermediate stage (multinodular)", "value": 2}, {"label": "Advanced stage (portal invasion with mets)", "value": 3}], "conditionality": "cp <= 2", "show_points": false, "optional": true}, {"type": "radio", "label_en": "Number of nodules", "name": "numnodes", "options": [{"label": "Single", "value": 1}, {"label": "Up to 3 nodules <3cm", "value": 2}], "conditionality": "cp <=2 && stage == 1", "show_points": false, "optional": false}, {"type": "radio", "label_en": "Portal pressure/bilirubin", "name": "portalpressure", "options": [{"label": "Normal", "value": 1}, {"label": "Increased", "value": 2}], "conditionality": "(cp <=2 && stage == 0) || (cp <=2 && stage == 1 && numnodes == 1)", "show_points": false, "optional": false}, {"type": "toggle", "label_en": "Associated diseases", "name": "assocdis", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(cp <=2 && stage == 0 && portalpressure == 2) || (stage <= 1 && numnodes == 2) || (cp <=2 && stage == 1 && numnodes == 1 && portalpressure == 2) ", "show_points": false, "optional": false}], "md5": "a79dc1d07ae0a103ba1e9cc4dd699e4a", "related_calcs": [{"calcId": 78, "short_title_en": "MELD Na (UNOS/OPTN)", "slug": "meld-score-model-end-stage-liver-disease-12-older"}, {"calcId": 340, "short_title_en": "Child-Pugh Score", "slug": "child-pugh-score-cirrhosis-mortality"}, {"calcId": 3824, "short_title_en": "mRECIST", "slug": "modified-response-evaluation-criteria-solid-tumors-mrecist"}]}